CHAT and Alzheimer disease: Most of the drugs currently approved by the FDA for AD patients, such as donepezil, galantamine, rivastigmine, etc., increase the residence time of ACh in the synaptic cleft, while in this study HA-E2 and E2 treatment (increasing the expression of ChAT) had the same effect.